Abeona Therapeutics

OOO poor unfortunate one, RDEB one

when you gonna schedule a time, Abeona

Ohh you make the stock run, stock run

skin coming off the line at Abeona

Pain will never stop, heal it up, such a lucky find

Always sensitive to the touch, get some peace of mind

Our, our, our, Abeona

Come be a patient unfortunate one

Post-procedure open your eyes, Abeona

Process is mystery, but agree

Wound down the length of my thigh, Abeona

Pain will never stop, heal it up, such a lucky find

Always sensitive to the touch, get some peace of mind

Our, our, our Abeona (2x)

When you gonna cash flow free, cash flow free

Is it just a matter of time, Abeona?

Saving lives is destiny, is destiny

Or is management in my mind, Abeona?

Pain will never stop, heal it up, such a lucky find

Always sensitive to the touch, get some peace of mind

Our, our, our Abeona (4x)

oooooooo My Abeona (3x)

Abeona Therapeutics, Inc. (ticker: ABEO) currently trades at $4.45 with a market capitalization of $245 million. Notably, as of the most recent quarter the firm has roughly $210 million of cash on its balance sheet. So, this novel gene therapy company is valued at an enterprise value of under $40 million.

So, why is The Stock Pawnshop interested in this name. First, it fits our theme of China vs USA. The two superpowers are in a race to dominate biotech, including curing rare diseases. Second, profitablility may come as early as next year. Lastly, at the current price, we feel that this small-cap biotech stock is derisked

RDEB = horrible. Eddie Vedder, lead singer of Pearl Jam, created a RDEB documentary called Matter Of Time and it’s worth watching. RDEB, or recessive dystrophic epidermolysis bullosa is a rare genetic skin condition that causes skin to tear easily, fall off, and blister.

The stock recently sold off heading into the third quarter because management pushed out it’s first patient treatment until the 4th quarter but left did not change its patient count for next year. We shall see if “oops” becomes a pattern. There are other therapies in the pipeline that can deliver royalty revenue as well. We think the stock is at least a double if management does a good job at controlling the controllables.